Table 3.
In the table are listed genes that were upregulated (in red) or downregulated (in green) in CML patients during treatment with imatinib.
| GENE ID | Function | Final effect | References |
|---|---|---|---|
| CCL5 | Activates NK | Anti-infective | (33) |
| CCR5 | Activates NK | Anti-infective | (34) |
| CD28 | Low in severe COVID-19 | Anti-infective | (35) |
| CD74 | Blocks macrophage activation | Pro-infective | (36) |
| CX3CR1 | High in antifungal resp | Anti-infective | (37) |
| CXCL16 | High in antiviral resp | Anti-infective | (38) |
| CXCR3 | High in T effector | Anti-infective | (39) |
| HAVCR2 | NK mature marker | Anti-infective | (40) |
| IFNG | Antiviral | Anti-infective | (41) |
| NFATC2 | Increases T cells | Anti-infective | (42) |
| TLR3 | Antiviral | Anti-infective | (43) |
| ARG1 | Immunosuppressive | Pro immune | (44) |
| CEACAM1 | Inhibits T lynf | Pro-infective | (45) |
| C3AR1 | Neutrophil chemotaxis antagonist | Anti-infective | (46) |
| COL17A1 | Induces IL7 that sustains T and B lynf | Anti-inflammation | (47) |
| FUT4 | Increases bacterial infections | Anti-infective | (48) |
| GSN | Increases NK apoptosis | Anti-infective | (49) |
| NECTIN1 | High in chlamydial infection | Anti-infective | (50) |
| RNASE2 | Antiviral | Pro-infective | (51) |
| RNASE3 | Antiviral | Pro-infective | (52) |
For each gene, the respective functions and the final effect after deregulation done by this TKI are indicated. In violet are the effects that could sustain a possible virus replication.